

Final - February 16, 2012

Thursday, February 23, 2012

8:00 Unfinished Business

Dr. Carol Baker (Chair, ACIP)

8:15 Agency Updates

CDC, CMS, DoD, DVA, FDA, HRSA, IHS, NVPO, NIH Information CDC and *Ex officio* members

8:30 Meningococcal Vaccines

· Introduction Dr. Cody Meissner (ACIP, WG Chair)
· GRADE (Grading of Evidence) assessment for MenACWY-D Information & Discussion Dr. Elizabeth Briere (CDC/NCIRD)
(Menactra) in children 9-23 months of age
· Updates to the Meningococcal Vaccines Statement Dr. Amanda Cohn (CDC/NCIRD)

10:00 *Break*

10:30 Measles, Mumps, Rubella (MMR) Vaccine

· Introduction Dr. Jon Temte (ACIP, WG Chair)
· Update: measles/rubella elimination consultation and documentation Dr. Mark Papania (CDC/NCIRD)
· Epidemiology of mumps in the United States Information & Discussion Mr. Albert Barskey (CDC/NCIRD)
· Impact of a third dose of MMR vaccine on the course of a mumps outbreak in an orthodox Jewish community Dr. Preeta Kutty (CDC/NCIRD)
· Impact of a third dose of MMR vaccine on mumps outbreak in Guam and economic impact of the outbreak Ms. Amy Parker Fiebelkorn (CDC/NCIRD)
· Summary of issues and discussion Dr. Huong McLean (CDC/NCIRD)

12:15 Public Comment

12:30 Adjourn

Acronyms

GRADE	Grading of Recommendations Assessment, Development and Evaluation
MenACWY-D	Meningococcal Polysaccharide (Serogroups A, C, Y and W-135) Diphtheria Toxoid Conjugate Vaccine
NCCDPHP	National Center for Chronic Disease Prevention and Health Promotion
NCEZID	National Center for Emerging and Zoonotic Infectious
NCHHSTP	National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
NCIRD	National Center for Immunization and Respiratory Diseases
TBD	To be determined
Tdap	Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine
WG	Work Group

